ReviewExpert review of cardiovascular therapy2010
Prevention of venous thromboembolism in obesity.
Review in Expert review of cardiovascular therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01916707 (Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- Portomesenteric Vein Thrombosis in Patients Undergoing Sleeve Gastrectomy: an Updated Systematic Review and Meta-Analysis of 101,914 Patients.Obesity surgery · 2023Pooled it
- Evaluation of prophylactic dosages of Enoxaparin in non-surgical elderly patients with renal impairment.BMC pharmacology & toxicology · 2019Trial
- Identifying the Bariatric Patient at Risk for Pulmonary Embolism: Prospective Clinical Trial Using Duplex Sonography and Blood Screening.Obesity surgery · 2015Trial
- Monitoring anti-Xa levels and thromboelastography in puerperal venous thromboembolism: a prospective cohort study.Frontiers in medicine · 2026Article
- Pulmonary Embolism in Acute Ischaemic Stroke: Evolving Evidence, Diagnostic Challenges, and a Novel Thromboinflammatory Axis Hypothesis.International journal of molecular sciences · 2025Review
- Multifunctional applications and research advances of low-molecular-weight heparin.Frontiers in pharmacology · 2025Review
- Being precise with anticoagulation to reduce adverse drug reactions: are we there yet?The pharmacogenomics journal · 2024Review
- Enhanced Recovery After Surgery Protocol in Bariatric Surgery Leads to Decreased Complications and Shorter Length of Stay.Obesity surgery · 2023Article
- Anti-Factor Xa Level Monitoring for Enoxaparin Prophylaxis and Treatment in High-Risk Patient Groups.HCA healthcare journal of medicine · 2023Review
- Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity.Frontiers in cardiovascular medicine · 2023Article
- Article
- Operative Techniques to Reduce Hip and Knee Arthroplasty Complications in Morbidly Obese Patients.Arthroplasty today · 2022Article
- Article
- Article
- Prophylactic Enoxaparin Dosing in Obese Orthopedic Patients: A Literature Search.Hospital pharmacy · 2020Review
- Type 2 Diabetes Is a Risk Factor for Suffering and for in-Hospital Mortality with Pulmonary Embolism. A Population-Based Study in Spain (2016-2018).International journal of environmental research and public health · 2020Article
- Emergence of institutional antithrombotic protocols for coronavirus 2019.Research and practice in thrombosis and haemostasis · 2020Article
- Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study.Clinical drug investigation · 2020Article
- Description of anti-Xa monitoring practices during low molecular weight heparin use.Journal of thrombosis and thrombolysis · 2019Article
- The Crashing Obese Patient.The western journal of emergency medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in hospitalized patients. Where appropriate, evidence-based methods of prophylaxis are implemented and the burden of VTE can be reduced substantially. Obesity, including morbid obesity, is associated with a high risk of VTE and, unfortunately, fixed doses of US FDA-approved anticoagulant regimens, including unfractionated heparins, low-molecular-weight heparins and factor Xa inhibitors, may not provide optimal VTE prophylaxis in these patients. Although the data are still limited, a rapidly growing body of literature and cumulative evidence suggests that anticoagulant dose adjustments in morbidly obese patients may optimize pharmacodynamic activity and reduce VTE risk. With the prevalence of morbid obesity continuing to rise, more high-quality clinical data are needed to better understand the pathobiology of VTE in obesity and provide effective, yet safe, prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.